Trade Names:Hespan- Injection 6 g per 100 mL in sodium chloride 0.9%
Trade Names:Voluven- Injection 6 g per 100 mL in sodium chloride 0.9%
Produces expansion of plasma volume. Does not have oxygen-carrying capacity or contain plasma protein, so it is not blood or plasma substitute.
Hetastarch is eliminated renally, and the mean t 1/ 2 is 17 days.
Adjunct therapy for plasma volume expansion in shock caused by hemorrhage, burns, surgery, sepsis, or other trauma; adjunct in leukapheresis to improve harvesting and increase yield of granulocytes.
Severe bleeding disorders; severe cardiac failure; renal failure with oliguria or anuria.
IV 500 to 1,000 mL/day; dosage does not usually exceed 1,500 mL/day.LeukapheresisAdults
IV 250 to 700 mL.
Store at room temperature, not exceeding 104°F. Do not freeze.
None well documented.
May alter coagulation and result in transient prolongation of prothrombin time (PT), partial thromboplastin time (PTT), bleeding and clotting times, decreased Hct and excessive plasma protein dilution; increases indirect bilirubin concentrations.
Submaxillary and parotid glandular enlargement.
Anaphylactoid reactions (eg, periorbital edema, urticaria, wheezing, mild temperature elevation); chills; mild influenza-like symptoms; muscle pain; peripheral edema of lower extremities.
Category C .
No data available.
May cause anaphylactoid reactions.
Caused by possibility of circulatory overload, take special care when administering to patients with renal impairment, at risk of pulmonary edema, or with CHF.
Copyright © 2009 Wolters Kluwer Health.